Please login to the form below

Not currently logged in
Email:
Password:

Roche's anti-obesity drug Xenical faces generic competition in UK

Teva launches first generic version of orlistat

Roche's anti-obesity brand Xenical (orlistat) is facing generic competition in the UK after Teva launched its version of the drug.

The company will sell its prescription-only version of Xenical at £27.60 for 120mg capsule x 84, under-cutting the £31.63 list price of Roche's branded version.

Kim Innes, commercial director at Teva, said: "We're delighted to be the first company to launch generic orlistat in the UK.

"As the UK's leading supplier of generics, we're pleased not only to have the widest portfolio of our competitors, but also to show that we're well-placed when it comes to innovation and being the first to market."

Xenical is indicated to treat obese patients with a body mass index (BMI) greater or equal to 30kg/m2, or overweight patients (BMI greater than or equal to 28kg/m2) with associated risk factors, in conjunction with a mildly hypocaloric diet.

The drug is also marketed in a reduced strength, non-prescription form by GlaxoSmithKline (GSK) as Alli, but the company is planning to divest it and other non-key OTC brands.

12th December 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics